Pharmaceuticals & Therapeutics

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.

A new partnership with logistics giant Uniphar will bring Zevra's breakthrough NPC therapy, MIPLYFFA, to patients in underserved regions worldwide.

After a turbulent year, the sleep apnea device maker aims to prove its rocky product launch is behind it and convince investors of a strong 2026.

Greenwich LifeSciences execs extend their stock lock-up to 6 years, signaling massive confidence in their breast cancer drug showing an 80% recurrence drop.

Adlai Nortye licenses its promising pan-RAS cancer inhibitor to ASK Pharm for Greater China in a deal valued at up to $230 million.

For the 13th consecutive year, Karmanos Cancer Institute is named a top US hospital, a distinction driven by patient safety and women's care preferences.

Diamyd Medical's pivotal Phase 3 trial gets a nine-month acceleration, raising hopes for a new precision therapy that preserves insulin production.

As pharma moves beyond small molecules, a new integrated platform helps developers navigate the challenges of PROTACs, peptides, and antibody drugs.

An FDA setback for its new mastitis drug prompts ImmuCell to double down on its profitable calf health franchise, First Defense®, in a major strategic shift.

A unique partnership brings accessible genetic testing to Boca Raton, using a community race to empower families with critical health knowledge.

In a landmark deal, BioMarin acquires Amicus Therapeutics, gaining high-growth drugs and reshaping the landscape for patients with rare genetic disorders.

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

Facing financial headwinds, Celularity lands a critical $12M from a top investor to push its ambitious anti-aging and regenerative therapies forward.

As pharma sells GLP-1s directly to patients, doctors are split on the new model. Is it a lifeline for access or a risk to integrated patient care?

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.

Picard Medical rings the NYSE bell, but its stock's volatile journey reflects the high-stakes gamble on its next-generation artificial heart technology.

The biotech upstart will present a bold pipeline, including a head-to-head trial against a market leader and a first-in-class autoimmune eye disease therapy.

Dr. Philip Golinsky’s alumni award from Life University marks a milestone for RxWellness and the growing trend of integrated, non-surgical patient care.

With trial data showing an average 23% body weight loss, Novo Nordisk's new combination drug CagriSema could usher in a powerful new era for medicine.